


FINALIST  
**SWISS  
MEDTECH**  
AWARD  
2022



DONATED BY:

**LICHTSTEINER  
FOUNDATION**

**sonova**  
HEAR THE WORLD

**straumann**group

**YPSOMED**  
SELF-CARE SOLUTIONS

## The jury



**Prof Dr Mirko Meboldt**

President of the Jury  
Chair of Product Development  
& Engineering  
ETH Zurich



**Prof Dr med Edouard Battegay**

Member of the Jury  
Head Innovation Hub, ICMC,  
University Zurich  
Owner IntelliXess AG



**Hans Ulrich Lehmann**

Member of the Jury  
Senior Vice President Technology  
Ypsomed



**Stephan Oehler**

Member of the Jury  
Head of Technology & Testing  
Straumann



**Sabina Sperisen**

Member of the Jury  
CEO  
Lichtsteiner Foundation



**Andi Vonlanthen**

Member of the Jury  
GVP Research & Development  
Sonova



## Lung-on-Chip System to improve drug development

**Company:**  
AlveoliX AG

**Foundation:**  
2019

**Headquarter:**  
Bern BE

**Founders:**  
Nina Hobi, Co-CEO  
Janick Stucki, Co-CEO

**Employees:**  
14


**Website:**  
› [alveolix.com](https://alveolix.com)

**Social Media**  
› [LinkedIn](#)

**AlveoliX aims to make organs-on-chips the new standard for preclinical decision-making and the leading alternative to animal experiments.**

AlveoliX provides advanced in-vitro models, called organs-on-chip. These models are used to better predict human responses in preclinical drug development and to gain more insight into human biology.

The combination of engineering and human biology is the success factor for creating a model, that more closely resembles the human organ microenvironment than standard models. Their technology is used to evaluate drug safety and efficacy during preclinical drug development to allow pharma companies to take a quicker decision on whether or not to proceed with a molecule. It contributes to the development of better and safer drugs for patients as well as to the advancement of personalized medicine. In addition, the use of our technology in drug development will help to reduce and replace unneeded animal testing in the future.





## The Optical Revolution in Blood Pressure Management

**Company:**  
Biospectal SA

**Foundation:**  
2017

**Headquarter:**  
Lausanne VD

**Founders:**  
Elliott Jones, CEO  
Prof. Patrick Schoettker,  
Chief Medical Officer

**Employees:**  
11

**Website:**  
› biospectal.com

**Social Media**  
› LinkedIn

**Anyone in the world with a smartphone can turn their device into a connected, smart, clinical-grade blood pressure monitor – anytime, anywhere.**

Hypertension affects 1.4bn people worldwide, making it the #1 chronic condition. Keeping it under control is a challenge. Biospectal OptiBP is a smartphone application and data platform that enables frequent and intelligent blood pressure tracking via a fingertip applied to a camera lens of a connected mobile device.

Biospectal OptiBP empowers people worldwide with a medical-grade solution that integrates directly into the ubiquitous smartphone already in their pocket or Biodics on their bedside table, enabling instantaneous blood pressure measurement and monitoring, anytime and anywhere. Biospectal OptiBP enables always connected patient and remote monitoring and is the only validated, pure software solution that meets the ISO 81060-2 international norm for accuracy for blood pressure measurement devices. No other blood pressure monitoring and management device on the market offers both the convenience and medical-grade accuracy of Biospectal OptiBP.





## Pioneering digital biomarkers in neurology

**Company:**  
Healios AG

**Foundation:**  
2012

**Headquarter:**  
Basel BS

**Founders:**  
Guilhem Dupont, CEO  
Corne de Jong, CFO

**Employees:**  
18

**Website:**  
› healios.io

**Social Media**  
› LinkedIn

**dreaMS smartphone technology meets the need for remote monitoring of patients with Multiple Sclerosis (MS) to support precision medicine.**

DreaMS helps people diagnosed with Multiple Sclerosis (PwMS) and supports neuroscience. DreaMS is an app based suite of challenges that assess the patient's neurological functioning while performing daily life activities and focuses on areas where PwMS typically experience impact of their disease, such as movement, dexterity, cognition and vision.

The smartphone application captures sensor data from the patient's smartphone which are then interpreted by regulated algorithms to calculate digital measures. Standard of care comprises an annual clinical examination and EDSS score at a hospital or clinic. DreaMS offers more objective, precise and frequent monitoring combined with convenience for patients who can perform these tests at home using standard devices. DreaMS is developed in collaboration with the Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB) which is part of the University Hospital of Basel. The program received support from Innosuisse.



Donated by:

**LICHTSTEINER  
FOUNDATION**

**sonova**  
HEAR THE WORLD

**straumann**group

**YPSOMED**  
SELFCARE SOLUTIONS

**SWISS MEDTECH**

Swiss Medical Technology Association | Freiburgstrasse 3 | CH-3010 Bern | Phone 031 330 97 79 | [office@swiss-medtech.ch](mailto:office@swiss-medtech.ch) | [www.swiss-medtech.ch](http://www.swiss-medtech.ch)